000 03278nam a2200421 a 4500
005 20250918150512.0
008 120127s2008 maua b 100 0 eng
020 _a9781573317597
_cRM385.22
020 _a1573317594
039 9 _a201202211046
_bruzini
_y01-27-2012
_zrazalis
040 _aUKM
090 _aQZ266.I61c 2009 9
090 _aQZ266
_b.I61c 2009 9
111 2 _aInternational Cancer Vaccine Symposium
_n(6th :
_d2008 :
_cNew York, N.Y.)
245 1 0 _aCancer vaccines :
_bsixth international symposium /
_cedited by Ralph Steinman, Jacques Banchereau, and Olivera J. Finn
246 3 0 _aCancer vaccines :
_b6th international symposium
246 1 _iConference title:
_aStages of cancer vaccine development
260 _aBoston, MA :
_bPublished by Blackwell Pub. on behalf of the New York Academy of Sciences,
_c2009
300 _avi, 121 p. :
_bill. ;
_c26 cm.
490 1 _aAnnals of the New York Academy of Sciences,
_x0077-8923 ;
_vv. 1174
500 _a'This volume presents manuscripts stemming from the conference'Sixth International Cancer Vaccine Symposium: Stages of Cancer Vaccine Development,' held at the New York Academy of Sciences Conference Center on Oct. 28-30, 2008.'--P. v
504 _aIncludes bibliographical references
505 0 _aSome scientific and organizational challenges in cancer immunology -- The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells -- Brain tumor immunotherapy with type-1 polarizing strategies -- Harnessing human dendritic cell subsets to design novel vaccines -- Dendritic cell-based vaccines for pancreatic cancer and melanoma -- Combining conventional therapies with intratumoral injection of autologous dendritic cells and activated T cells to treat patients with advanced cancers -- Witch hunt against tumor cells enhanced by dendritic cells -- Harnessing CD1D-restricted t cells toward antitumor immunity in humans -- Immunity against cyclin B1 tumor antigen delays development of spontaneous cyclin B1-positive tumors in p53-/- mice -- Targets of protective tumor immunity -- Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer -- Harnessing dendritic cells to generate cancer vaccines -- Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells -- Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model -- Hematopoietic stem and progenitor cells and the inflammatory response
650 2 _aCancer vaccines
_vCongresses
650 7 _aKrebs (Medizin)
_2idszbz
650 7 _aVakzine.
_2idszbz
700 1 _aSteinman, Ralph M.
700 1 _aBanchereau, Jacques
700 1 _aFinn, Olivera J.
830 0 _aAnnals of the New York Academy of Sciences ;
_vv. 1174.
_x0077-8923
856 4 2 _3Publisher description
_uhttp://www.loc.gov/catdir/enhancements/fy1011/2010487333-d.html
907 _a.b15234708
_b2021-05-28
_c2019-11-12
942 _c01
_n0
_kQZ266.I61c 2009 9
914 _avtls003487019
991 _aJabatan Bioperubatan, KKL
998 _ad
_b2012-01-01
_cm
_da
_feng
_gmau
_y0
_z.b15234708
999 _c507570
_d507570